TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female patients ≥6 to \<18 years of age with a diagnosis of 1. Atopic Dermatitis whose disease cannot be adequately controlled with topical medications~2. Minimum disease severity, as defined by Investigator's Global Assessment (IGA)~   1. IGA = 3 or 4 in adolescents ≥12 to \<18 year of age~  2. IGA = 4 in children ≥6 to \<12 years of age~Key Exclusion Criteria:~1. Recent treatment (within specific time windows before the baseline visit) with systemic immunosuppressive agents for eg. Systemic corticosteroids, live (attenuated) vaccines and other investigational drugs including biologics~2. History of any of the following infections:~   1. Any systemic infection requiring treatment within 4 weeks before the baseline visit~  2. Superficial skin infections within 1 week before the baseline visit~  3. Known history of HIV infection~  4. History of seropositivity to hepatitis B or C screening tests~  5. History of clinical endoparasitosis (ie, helminthic infection) within 12 months before the baseline visit, or high risk of helminthic infection, unless subsequent medical assessments (e.g. stool exam, blood tests, etc.) have ruled out the possibility of parasite infection/infestation~3. History of malignancy within 5 years before the baseline visit~4. Persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\]) more than 3 times the upper limit of normal (ULN) during the screening period~5. Presence of any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study~6. Presence of skin comorbidities that may interfere with study assessments~7. Females patients who are pregnant or breastfeeding~8. Female patients who are of reproductive potential and are sexually active, who are unwilling to use adequate methods of contraception

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Cohort 1 will receive dupilumab dosing regimen 1
- Cohort 2 (Type: EXPERIMENTAL): Cohort 2 will receive dupilumab dosing regimen 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NIR Fluorescence Imaging Technique in Thoracic Surgery With ICG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pulmonary nodules undergoing thoracoscopy or thoracotomy~* Esophageal cancer patients who underwent radical surgery~* Preoperative liver function is normal~* No indocyanine green and iodine allergies, and indocyanine green skin test negative~* Volunteered to participate in this study and signed informed consent in this study~Exclusion Criteria:~* Preoperative liver dysfunction~* Indocyanine green or iodine allergies, or indocyanine green skin test positive~* Not combined with other well-controlled comorbidities~* Clinicians considered unsuitable for enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Indocyanine green (Type: EXPERIMENTAL): This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between (and including) ages 18-70 and taking at least 5 mg/day of prednisone equivalents for at least 3 months and anticipating continued treatment at the same dose for at least 20 additional weeks will be eligible for enrollment.~Exclusion Criteria:~* Patients with a history of allergic reaction or other contraindication to memantine therapy or with other unstable medical conditions (e.g. recent myocardial infarction, diabetes with poor glycemic control) will not be allowed to participate.~* Pregnant or nursing women or women of childbearing age who will not use University of Texas Southwestern (UTSW) Institutional Review Board (IRB) approved methods of avoiding pregnancy will be excluded from the study.~* Those with a history of mental retardation, dementia, or other severe cognitive disorders will also be excluded from the study.~* Patients with baseline RAVLT total words recalled normative score \> 55 will be excluded to avoid including persons with exceptionally good declarative memory at baseline.~* Subjects who do not speak English will be excluded because many of the outcome measures used in this study are not validated in languages other than English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \> 18 years,\<70~2. Will benefit from treatment~3. Not suffering from physical condition~4. Resident at the prayer camp~5. Not likely to be discharged from camp within six weeks~6. Speaks either English or twi~7. Able to give consent~8. Not already on medication~Exclusion Criteria:~1. likely to be discharged within 6 weeks of commencement of medication~2. Patients already on medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No intervention
- Experimental (Type: EXPERIMENTAL): The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who show:~  * Keratoconjunctival disorder confirmed with vital dye staining~ * Abnormal Schirmer score results~Exclusion Criteria:~* Eye disease that needs therapy other than that for dry eye~* Those who need to wear contact lenses during the clinical study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 3% DE-089 (Type: EXPERIMENTAL): None
- 0.1% HA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of recurrent medulloblastoma or CNS germ cell tumor~  * Histologic review of the primary intracranial or spinal cord tumor required~    * Biopsy and reduction of tumor bulk prior to study encouraged but not required~* No more than 1 prior primary therapy (radiotherapy or chemoradiotherapy) and/or 1 prior salvage therapy~  * Patients with progression on salvage therapy ineligible~* Minimal residual disease (tumor bulk no more than 1.5 cm) or in second clinical complete remission (CR)~* Bone marrow infiltration with or without mass lesions or isolated abnormal CSF cytology as the only manifestation of recurrent disease allowed if a clinical CR is first achieved with conventional therapy~PATIENT CHARACTERISTICS:~Age:~* 2 to 25~Performance status:~* Karnofsky 80-100%~Life expectancy:~* More than 8 weeks~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 mg/dL~* SGPT less than 80 IU~Renal:~* Creatinine less than 1.2 mg/dL~Cardiovascular:~* LVEF normal~Other:~* No infection~* Able to tolerate vigorous hydration~* Not pregnant~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* Prior cyclophosphamide or ifosfamide allowed~Endocrine therapy:~* No concurrent dexamethasone as an antiemetic~* Other concurrent corticosteroids allowed~Radiotherapy:~* See Disease Characteristics~* Pretransplantation radiotherapy boost allowed~Surgery:~* See Disease Characteristics~* Pretransplantation surgery allowed~Other:~* At least 4 weeks since prior therapy except corticosteroids

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Ablative chemo followed by autologous bone marrow (ABM) rescue (Type: EXPERIMENTAL): Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females with type 2 diabetes (receiving pharmacologic treatment for at least 6 months or longer) with stable diabetes therapy~* Lipid-lowering therapy must be unchanged for at least 4 weeks or more~* Subjects receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 100 mg/dL~* Subjects not receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 130 mg/dL~Exclusion criteria:~* New York Heart Association (NYHA) class III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes or poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Atorvastatin (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Evolocumab Q2W + Atorvastatin (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Evolocumab QM + Atorvastatin (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or postmenopausal women~* 55 years of age or older~* Diagnosis of MCI due to AD or mild AD~* MMSE \> 20 at screen~* Capacity to provide informed consent~* Residing in the community with a caregiver able to accompany the patient to clinic visits~* No medical contraindications to participation~* Willingness to comply with study procedures~Exclusion Criteria:~* Use of benzodiazepines, sedative/hypnotics, anticonvulsants, antipsychotics, and other drugs that might interact with the GABA-A receptor complex~* Seizure disorder, history of stroke, focal brain lesion, traumatic brain injury, substance abuse, malignancy~* Clinically significant laboratory or ECG abnormality~* MRI indicative of any other significant abnormality, including but not limited to evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions~* Any condition that would contraindicate an MRI such as the presence of metallic objects in the eyes, skin, heart, or body

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopregnanolone 2 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Allopregnanolone 4 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Allopregnanolone 6-18 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo injection (intravenous solution) once per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant in the Management of Biological Therapies-related Severe Pruritus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed diagnosis of solid tumor~* treatment with anti-EGFR antibodies or TKIs~* first onset of severe pruritus during treatment (≥7 on Visual Analogue Scale (VAS) score)~Exclusion Criteria:~* oral treatment with antimycotics during 4 weeks preceding enrolment~* topical treatment during the previous 2 weeks~* concomitant,chronic renal or hepatic insufficiency , skin infection or dermatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: OTHER): Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
- Aprepitant after anti-itch standard therapy (Type: OTHER): Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged ≥18 years~* Patients with newly diagnosed, histologically confirmed, International Federation of Gynecology and Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone initial surgery up to 3 weeks before randomization and are selected to receive first line Standard of Care chemotherapy (optional prolongation to 6 weeks after surgery)~* Optimally debulked (zero residuum) or maximal residuum \<1cm~* Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2~Exclusion Criteria:~* FIGO I,II,IV epithelial ovarian cancer~* FIGO III clear cells epithelial ovarian cancer~* Non-epithelial ovarian cancer (OvCa), borderline tumors (tumors of low malignant potential)~* Post-surgery residual disease with lesion(s) \>1cm~* Prior or current systemic anti-cancer therapy for ovarian cancer \[for example chemotherapy, monoclonal antibody therapy (bevacizumab), tyrosine kinase inhibitor therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy\]~* Previous or concurrent radiotherapy to the abdomen and pelvis~* Malignancy other than epithelial ovarian cancer, except those that have been in clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the cervix or non-melanoma skin carcinomas~* Patient co-morbidities:Human immunodeficiency virus (HIV) positive, human T-lymphotropic virus (HTLV) positive, Active hepatitis B (HBV), active hepatitis C (HCV), active syphilis~* Evidence of active bacterial, viral or fungal infection requiring systemic treatment~* Clinically significant cardiovascular disease including:~Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia requiring medication Uncontrolled hypertension Myocardial infarction or ventricular arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (EF) \< 40 percent or serious cardiac conduction system disorders, if a pacemaker is not present

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCVAC/OvCa with Standard of Care (Type: EXPERIMENTAL): DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
- DCVAC/OvCa sequentially chemotherapy (Type: EXPERIMENTAL): DCVAC/OvCa sequentially after chemotherapy
- Standart of Care (Type: ACTIVE_COMPARATOR): Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult females who have bilateral myalgia based on Diagnostic Criteria for TMD (DC-TMD) criteria and current pain intensity (≥4 out of 10, where 0 is no pain and 10 is the worst pain ever) on both sides.~Exclusion Criteria:~* Those who have a history or were diagnosed with systemic musculoskeletal disorders or rheumatologic diseases (e.g. fibromyalgia, muscular atrophy).~* Certain conditions such as neoplasms or fractures.~* Neuropathies or neurological disorders.~* Participants who are currently taking muscle relaxants or analgesics.~* Those who have undergone any form of physical therapy within the last 60 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: 0.4 Watts/Sq cm 50% Duty cycle (Type: EXPERIMENTAL): 0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
- B: 0.4 Watts/Sq cm 100% Duty cycle (Type: EXPERIMENTAL): 0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
- C: 0.8 Watts/Sq cm 50% Duty cycle (Type: EXPERIMENTAL): 0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
- D: 0.8 Watts/Sq cm 100% Duty cycle (Type: EXPERIMENTAL): 0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete